Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Conference Coverage: Breaking News on Head and Neck Studies from the American Society for Radiation Oncology 58th Annual Meeting

Breaking News on Head and Neck Studies from the American Society for Radiation Oncology's 58th Annual Meeting.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The immunotherapeutic blockade of checkpoint inhibition that has resulted in stellar improvements in patient outcomes in melanoma and non-small cell lung cancer is now a likelihood for patients with head and neck cancer. Join us as Dr. Tanguy Seiwert discusses the mechanistic basis of checkpoint inhibition and the clinical data demonstrating the efficacy of anti-PD-1 agents in patients with head and neck cancer. Also discussed is the potential value of synergism between anti-checkpoint immunotherapy and current standards of care in head and neck cancer, as well as the growing relevance of biomarkers in identifying patients who will most benefit from immunotherapy.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Tanguy Seiwert, MD
    Associate Program Director Head and Neck Cancer Program
    University of Chicago
    Chicago, Illinois

    Faculty’s disclosure

    Dr. Seiwert receives consulting fees from Merck/MSD, Bristol-Myers Squibb, Astra-Zeneca, Eli Lilly and Company, Amgen, Celgene, Innate Pharma, and Merck Serono.


    • Sean T. Barrett, CHCP has nothing to disclose.
    • Colleen Braun has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Barry Fiedel, PhD has nothing to disclose.

    Planners and Managers

    The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. 

  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pharmacists, and registered nurses.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Define the mechanistic basis for checkpoint inhibition and the value of its use as a pharmacologic target.
    2. Demonstrate an understanding of the clinical efficacy of intervention with anti-checkpoint immunotherapy compared with current standards of care.
    3. Appreciate potential synergies between anti-checkpoint immunotherapy and current treatment approaches including radiotherapy, chemotherapy, and surgery.
    4. Utilize immunotherapy-related biomarkers in the identification of patients most likely to respond to immunotherapy.
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - 0809-9999-16-501-H01-P)

    Type of Activity: Knowledge

    ACPE release date: 10/13/2016

    For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    Continuing Nursing Education

    The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.  This educational activity for 0.3 contact hour(s) is provided by the Postgraduate Institute for Medicine.

    For Pharmacists and Nurses:

    If you wish to receive acknowledgment for completing this activity, please complete the evaluation on  On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 12022.  Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.  

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education

    Co-provided by Postgraduate Institute for Medicine and Prova.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.